logo-loader
viewProactive Group

Fiat Chrysler to spin off components business Magneti Marelli

The separation is expected to be completed by early 2019

Fiat Chrysler
The carmaker wants to focus on its core business

Fiat Chrysler Automobiles NV (NYSE:FCAU) plans to spin off its components business, Magneti Marelli, to focus on its core portfolio and strengthen its capital position.

The company said the separation is expected to be completed by early 2019 after which shares will be distributed to Fiat shareholders. Shares of Magneti Marelli will be listed on the Milan Stock Exchange.

Spin-off part of 5-year business plan

Chief executive Sergio Marchionne said in a statement on Thursday that the move would allow the carmaker to focus on its core business.

"The separation will deliver value to FCA shareholders, while providing the operational flexibility necessary for Magneti Marelli’s strategic growth in the coming years,” Marchionne said.

The spin-off is part of the company’s five-year business plan to be announced in June before Marchionne steps down early next year.

The plan is subject to regulatory approvals and final approval by Fiat's board of directors.

The news comes as the auto industry comes under pressure to respond to the shift away from diesel and petrol vehicles towards electric and hybrid.

GKN PLC (LON:GKN) had planned to separate its automotive business, Driveline, and merge it with Dana Inc (NYSE:DAN) after failing to meet targets to improve profit and cash flow.

However, GKN shareholders voted in favour of a hostile takeover bid from Melrose Industries PLC (LON:MRO) instead.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

9 hours, 8 minutes ago

2 min read